The observation that THRSP inhibits glycolysis and HCC progression and serves as a prognostic marker for patient survival further underscores its potential as a therapeutic target for cancer treatment and glucose metabolism regulation in HCC. This evidence concerns the gene THRSP and hepatocellular carcinoma.